ipilimumab,nivolumab
bms,dev therapeutics
['nivo', 'ipi/', 'sclc', 'sarcoma', 'nsclc']
#asco22 dev therapeutics/io: unifying gut microbial signatures assoc with response to neoadjuvant ipi/nivo across 3 tumour types (mel, nsclc, sarcoma) responders to io had tls &amp; bcell signatures, which in turn assoc with baseline ruminococcus 
Thoracic Oncologist focused on immunotherapy for lung cancer & immune toxicity. Beaumont RCSI Cancer Centre Dublin; Adjunct Asst Prof Johns Hopkins University